

Single-dose psychedelic boosts brain flexibility for weeks, peer-reviewed study finds

A single dose of a psychedelic improves cognitive flexibility in mice for at least three weeks. This has implications for depression, PTSD, and Alzheimer's.

ANN ARBOR, MI, UNITED STATES, April 22, 2025 /EINPresswire.com/ -- In a groundbreaking research study, University of Michigan researchers have discovered that a single dose of a psychedelic compound can enhance cognitive flexibility—the brain's ability to adapt to changing circumstances—for weeks after administration, potentially revolutionizing treatments for depression, PTSD, and neurodegenerative diseases.

The study, published today in the journal <u>Psychedelics</u>, demonstrates that mice treated with a single dose of 25CN-NBOH, a selective serotonin 2A receptor agonist, showed markedly improved performance in reversal learning tasks compared to control groups when tested 2-3 weeks after treatment.



Illuminating Flexibility: Single-Dose Psychedelics and Cognitive Adaptation. The figure depicts a mouse with a lightbulb, symbolizing the remarkable cognitive enhancements discovered in psychedelic research. Against a vibrant, radiating background, this i

Key Findings

"What makes this discovery particularly significant is the sustained duration of cognitive benefits following just one psychedelic dose," explains Professor Omar J. Ahmed, the study's senior, corresponding author from the University of Michigan's Department of Psychology. "We observed enhanced learning adaptability that persisted for weeks, suggesting these compounds may induce lasting and behaviorally meaningful neuroplasticity changes in the prefrontal cortex."

Using an innovative automated sequential learning paradigm, researchers measured how effectively mice could adapt to rule reversals—a standard test for cognitive flexibility. The psychedelic-treated mice demonstrated superior adaptability compared to saline controls, with enhanced task efficiency, higher percentages of correct trials, and increased reward acquisition during the reversal phase.

Implications for Brain Science

The results complement existing cellular research showing psychedelic-



Experimental timeline and overview. (A) Experimental timeline (65). (B) Schematic of the SEQFR2-forward protocol. Mice have to sequentially poke left and then right within 30 s to earn a reward pellet. (C) Schematic of the SEQFR2-reversal protocol. Mice n

induced structural remodeling in the prefrontal cortex but uniquely demonstrate sustained cognitive benefits persisting long after the immediate effects of the drug have dissipated.

"

This suggests that a single dose of a psychedelic isn't just temporarily altering perception, but potentially inducing lasting beneficial changes in brain function." *Elizabeth J. Brouns* As interest in psychedelic medicine continues to grow, this research raises intriguing questions about how psychedelics might reshape neural pathways governing flexible thinking. Could these compounds potentially reopen critical periods of brain plasticity? What molecular mechanisms underlie these long-lasting cognitive improvements? How might the timing and frequency of administration affect long-term neuroplasticity?

"The current study focused on the long-term effects of a

single psychedelic dose. A key question is what happens with two, three, or even twenty doses taken over several months. Is every additional dose increasingly beneficial for flexible learning or is there a plateau effect or even a negative effect of too many doses? These are important questions to answer next in the quest to make psychedelic medicine more rational and mechanistic," according to Dr. Ahmed.

Sex Differences and Clinical Potential

Importantly, the study found that both male and female mice showed significant improvements in cognitive flexibility, suggesting the potential broad applicability of psychedelic therapy across

biological sexes.

"The most striking aspect of our findings is that these cognitive benefits were measured 15-20 days after a single psychedelic administration," notes Elizabeth J. Brouns, first author of the study. "This suggests that a single dose of a psychedelic isn't just temporarily altering perception, but potentially inducing lasting beneficial changes in brain function."

Methodological Advances

The study's automated behavioral task

p.genomicpress.com Psychedelics e OPEN Single-dose psychedelic enhances cognitive flexibility and reversal learning. in mice weeks after administration in mice weeks after administration Elizabeth J. Brouns¹ ©, Tyler G. Ekins^{1,2} Ø, and Omar J. Ahmed^{1,2,3,4,5} Ø ¹Department of Psychology, University of Michigan, Ann Arbor, MI 48109 ³Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI 48109 ³Department of Bioinformatics University of Michigan, Ann Arbor, MI 48109 ⁶Center of Computational Medicine & Bioinformatics University Michigan, Ann Arbor, MI 48109 ⁶Center of Computational Medicine & Bioinformatics University Michigan, Ann Arbor, MI 48109 ⁶Center of Computational Medicine & Bioinformatics University Michigan, Ann Arbor, MI 48109 ⁶Center of Computational Machine, Machine Machine and Bioinformatics University Michigan, Ann Arbor, Mi 48109 ⁶Center of Computational Machine, Machine and Science and Anarbor, Mi 48109 ⁶Center of Computational Machine, Bioinformatics Uni

Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration

represents a significant methodological advance for evaluating flexible learning, enabling researchers to efficiently evaluate cognitive flexibility in future investigations of psychedelic compounds. This high-throughput approach could accelerate the development of targeted psychedelic therapies for specific cognitive deficits.

The full Psychedelics peer-reviewed research article, titled "Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration" is available on 22 April 2025 in Psychedelics. The research includes Dr. Tyler Ekins as a co-author and was supported by the National Institutes of Health and the University of Michigan Eisenberg Family Depression Center. The article is freely available online at https://doi.org/10.61373/pp025r.0002.

About the Journal - Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671) is a peer reviewed medical research journal published by <u>Genomic Press</u>, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society.

Dr. Omar J. Ahmed University of Michigan ojahmed@umich.edu Visit us on social media: Facebook X LinkedIn Instagram Other

This press release can be viewed online at: https://www.einpresswire.com/article/804545465

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.